ImmuNovus
Denton, US · Founded 2022 · Delaware corporation
Immunovus develops software that creates a personal immune "digital twin" to model and forecast an individual's immune trajectory, integrating and interpreting health data such as test results. It targets consumers, clinicians, and pharmaceutical companies, supporting scenario forecasting, personalized clinical trials, drug discovery, and drug repurposing.
Founders & leadership
ImmuNovus was founded in 2022 by Tomas Helikar.
TH
Tomas HelikarinFounder
Reported raises · per SEC filings
Form D private placements$1M disclosed across 1 round · 2026
▶$1MraisedJul 2026 · 2 investors · Other TechnologyRule 506(b)
▶$1MraisedJul 2026 · 2 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Tomas HelikarExecutive Officer
- Offering amount
- $5M
- Amount sold
- $1M
- Minimum investment
- $10
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does ImmuNovus do?
- Immunovus develops software that creates a personal immune "digital twin" to model and forecast an individual's immune trajectory, integrating and interpreting health data such as test results. It targets consumers, clinicians, and pharmaceutical companies, supporting scenario forecasting, personalized clinical trials, drug discovery, and drug repurposing.
- Who founded ImmuNovus?
- ImmuNovus was founded by Tomas Helikar in 2022.
- How much funding has ImmuNovus raised?
- ImmuNovus has disclosed $1M raised across 1 round.
- Where is ImmuNovus headquartered?
- ImmuNovus is headquartered in Denton, US.